FDA Inspection 1154331 — Salil U. Nadkarni, DO

Salil U. Nadkarni, DO — FEI 3020134804

The FDA completed an inspection of Salil U. Nadkarni, DO on September 24, 2021 in Los Angeles, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 24, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Los Angeles, CA (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
756021 CFR 312.60FD-1572, protocol compliance